Karyopharm Therapeutics (KPTI) Misses Q2 EPS by 8c

Karyopharm Therapeutics (NASDAQ: KPTI) reported Q2 EPS of ($0.84), $0.08 worse than the analyst estimate of ($0.76). Revenue for the quarter came in at $59 thousand versus the consensus estimate of $40 thousand.

For earnings history and earnings-related data on Karyopharm Therapeutics (KPTI) click here.

You May Also Be Interested In

• Lindsay (LNN) Tops Q3 EPS by 18c, Misses on Revenue
• Roblox falls 4% in pre-market as Wells Fargo bookings caution reasserts
• Rivian raises 2026 delivery outlook after Q2 results top guidance